top of page

The CEO of IDRx describes early GIST data at ASCO24 that he believes could point to a best-in-class asset

Tim Clackson explains how IDRX-42 has been designed to eliminate resistance mutations that the current standard of care cannot handle, and discusses P1/b ORR data presented at ASCO today.


Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight


Breakthrough Properties is a life science real estate company that is exclusively focused on delivering cutting-edge environments for the life science industry. With a portfolio of roughly 5 million square feet across the US, UK and continental Europe, Breakthrough has emerged as a leading partner for high-growth biotechs and pharmas around the world. 

bottom of page